Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2004-02-13
2008-10-07
Henley, III, Raymond J (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S336000, C514S557000, C514S647000, C514S652000, C514S653000
Reexamination Certificate
active
07432247
ABSTRACT:
The present invention provides compositions and methods for maintaining cardiac function by administering dichloroacetate (DCA) in combination with an inotrope.
REFERENCES:
patent: 5643951 (1997-07-01), Stacpoole et al.
patent: 6076528 (2000-06-01), Marangos et al.
patent: 6423705 (2002-07-01), Tracey et al.
patent: 6693133 (2004-02-01), Lopaschuk et al.
patent: WO95/31986 (1995-11-01), None
patent: WO99/17763 (1999-04-01), None
Agbenyega, T., et al., Population kinetics, efficacy, and safety of dichloroacetate for lactic acidosis due to severe malaria in children, J. Clin. Pharmacol. 43:386-396 (2003).
Allard, M.F., et al., Contribution of oxidative metabolism and gycolysis to ATP production in hypertropied hearts, Am. J. Physiol., 267(2 Pt 2):H742-50 (1994).
Bersin, R.M., et al., Dichloroacetate as metabolic therapy for myocardial ischemia and failure, Am. Heart J., 134(5 Pt 1):841-55 (1997).
Bersin, R.M., et al., Improved hemodynamic function and mechanical efficiency in congestive heart failure with sodium dichloroacetate, J. Am. Coll. Cardiol., 23(7):1617-24 (1994).
Burns, A.H., et al., Inotropic interactions of dichloroacetate with amrinone and ouabain in isolated hearts from endotoxin-shocked rats, J. Cardiovascular Pharmacology, 11:379-386 (1988).
Chang, M.C., et al., Redefining cardiovascular performance during resuscitation: ventricular stroke work, power,and the pressure-volume diagram, J. Trauma, 45(3):470-8 (1998).
Collins-Nakai, R.L., et al., Dichloroacetate acid (DCA) after open heart surgery in infants and children, Canadian Journal of Cardiology, Pulsus Group, Inc., XX, 11(106E):148 (1995).
Currie, P.F., et al., Immunopathogenesis of HIV-related heart muscle disease: current perspectives, AIDS, 17 (suppl. 1)):S21-S28 (2003).
Gamble, J., et al., Glycolysis and glucose oxidation during reperfusion of ischemic hearts from diabetic rats, Biochim. Biophys Acta, 1224(2):191-9 (1994).
Gargaglioni, L.H., et al., Lactate as a modulator of hypoxia-induced hyperventilation, Respir. Physiol Neurobiol., 138(1):37-44 (2003).
Gutierrez, G., et al., Clinical review: Hemorrhagic shock, Critical Care, 8 (DOI 10.1186/cc2851), date not available.
Hall, J.L., et al., Increased cardiac fatty acid uptake with dobutamine infusion in swine is accompanied by a decrease in malonyl CoA levels, Cardiovascular Research 32:879-885 (1996).
Heckbert, S.R., et al., Outcome after hemorrhagic shock in trauma patients, J. Trauma-Injury Infection & Critical Care, 45(3):545-549 (1998).
Kline, J.A., et al., Activation of pyruvate dehydrogenase improves heart function and metabolism after hemorrhagic shock, J. Mol. Cell Cardiol., 29:2465-2474 (1997).
Kline, J.A., et al., Heart function after severe hemorrhagic shock, Shock, 12(6):454-61 (1999).
Kudej, R.K., et al., Brief increase in carbohydrate oxidation after reperfusion reverses myocardial stunning in conscious pigs, Circulation 106:2836-2841 (2002).
Lipschultz, S.E., et al., Left ventricular structure and function in children infected with human immunodeficiency virus: the prospective P2C2 HIV multicenter study. Pediatric pulmonary and cardiac complications of vertically transmitted HIV infection (P2C2 HIV) study group, Circulation 97(13):1246-56 (1998).
Liu, B., et al., Cardiac efficiency is improved after ischemia by altering both the source and fate of protons, Circulation Research, 79:940-948 (1996).
Liu, Q., et al., High levels of fatty acids delay the recovery of intracellular pH and cardiac efficiency in post-ischemic hearts by inhibiting glucose oxidation, J. Am. Coll. Cardiol., 39:718-25 (2002).
Lopaschuk, G.D., et al., An imbalance between glycolysis and glucose oxidation is a possible explanation for the detrimental effects of high levels of fatty acids during aerobic reperfusion of ischemic hearts, J. Pharmacol. Exp. Ther., 264(1):135-44 (1993).
Lopaschuk, G.D., Alterations in fatty acid oxidation during reperfusion of the heart after myocardial ischemia, Am. J. Cardiol. 80(3A):11A-16A (1997).
Lopaschuk, G.D., et al. Alterations in myocardial fatty acid metabolism contribute to ischemic injury in the diabetic, Can J. Cardiol., 5(6):315-20 (1989).
Matetsky, S., et al., Acute myocardial infarction in human immunodeficiency virus-infected patients, Arch. Intern Med., 163(4):457-60 (2003).
McVeigh, J.J., et al., Dichloroacetate stimulation of glucose oxidation improves recovery of ischemic rat hearts, Am. J. Physiol. 259:H1079-H1085 (1990).
Nicholl, T.A., et al., Effects of free fatty acids and dichloroacetate on isolated working diabetic rat heart, Am. J. Physiol., 261(4 Pt 2):H1053-9 (1991).
Rozanski, G.J., et al., Gluthathione and K+channel remodeling in posinfarction rat heart, Am. J. Physiol. Heart Circ. Physiol. 282(6):H2346-H2355 (2002).
Rupp, H., et al., The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure, Herz, 27:621-36 (2002).
Saddik, M., et al., Acetyl-CoA carboxylase regulation of fatty acid oxidation in the heart, J. Biol. Chem., 268(34):25836-25845 (1993).
Southard, S., et al., A—Evaluation of dichloroacetate (DCA) as adjunct therapy in severe malaria POC, Commerce Business Daily Issue of Nov. 5, 1996 PSA #1715, National Institute of Allergy & Infectious Diseases, Contract Management Branch, Solar Building, Room 3C07, 6003 Executive Blvd. MSC 7610, Bethesda, MD 20892-7610.
Stacpoole, P.W., et al., Efficacy of dichloroacetate as a lactate-lowering drug, J. Clin. Pharmacol., 43:683-691 (2003).
Stanley, W.C., et al., Pyruvate dehydrogenase activity and malonyl CoA levels in normal and ischemic swine myocardium: Effects of dichloroacetate, J. Mol. Cell Cardiol., 28:905-914 (1996).
Stanley, W.C., et al., Regulation of energy substrate metabolism in the diabetic heart, Cardiovascular Research, 34:25-33 (1997).
Starc, T.J., et al., Incidence of cardiac abnormalities in children with human immunodeficiency virus infection: The prospective P2C2 HIV study, J. Pediatr. 141(3):327-34 (2002).
Stout, T.T., et al., Electrocardiographic changes in acute malaria, Neth J. Med. 37(3-4):124-8 (1990).
Vary, T.C., et al., Sepsis alters pyruvate dehydrognase kinase activity in skeletal muscle, Mol. Cell Biochem. 198(1-2):113-8 (1999).
Wambolt, R.B., et al. Dichloroacetate improves postischemic function of hypertrophied rat hearts, J. Am. Coll. Cardiol., 36:1378-85 (2000).
Watts, J.A., et al., Metabolic dysfunction and depletion of mitochondria in hearts of septic rats, J. Molecular and Cellular Cardiology, 36:141-50 (2004).
Yan, M., et al., 3-O-methyldobutamine, a major metabolite of dobutamine in humans, Drug Metabolism and Disposition: the Biological Fate of Chemicals, 30(5):519-524 (2002).
Zenati, M.S., et al., A brief episode of hypotension increases mortality in critically III trauma patients, J. Trauma-Injury Infection & Critical Care, 53(2):232-237 (2002).
Collins-Nakai Ruth
Lopaschuk Gary D.
Henley, III Raymond J
Pillsbury Winthrop Shaw & Pittman LLP
The Governors of the University of Alberta
LandOfFree
Methods of cardioprotection using dichloroacetate in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of cardioprotection using dichloroacetate in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of cardioprotection using dichloroacetate in... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4002262